Get the Stockscreener App
6.51
8.14%
0.49
Pre-market:
6.11
-0.40
-6.14%
Electrocore Inc stock is traded at $6.51, with a volume of 182.78K.
It is up +8.14% in the last 24 hours and down -18.63% over the past month.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
See More
Previous Close:
$6.02
Open:
$6.02
24h Volume:
182.78K
Relative Volume:
1.25
Market Cap:
$42.30M
Revenue:
$16.03M
Net Income/Loss:
$-18.83M
P/E Ratio:
-1.86
EPS:
-3.5
Net Cash Flow:
$-14.87M
1W Performance:
+10.71%
1M Performance:
-18.63%
6M Performance:
-27.51%
1Y Performance:
+15.22%
1-Day Range:
$6.02
$7.07
1-Week Range:
$5.57
$7.07
52-Week Range:
$5.02
$19.49
Electrocore Inc Stock (ECOR) Company Profile
Name
Electrocore Inc
Sector
Industry
Phone
973-290-0097
Address
200 FORGE WAY, ROCKAWAY
Compare ECOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ECOR
Electrocore Inc
|
6.51 | 42.30M | 16.03M | -18.83M | -14.87M | -3.50 |
|
ABT
Abbott Laboratories
|
129.89 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
93.58 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
339.59 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
81.80 | 104.24B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.20 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Electrocore Inc Stock (ECOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-20 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-14-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-26-19 | Resumed | Cantor Fitzgerald | Neutral |
| May-30-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-15-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-09-19 | Initiated | Noble Capital Markets | Outperform |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Electrocore Inc Stock (ECOR) Latest News
ElectroCore (ECOR) Reports Positive Outcomes for Traumatic Brain Injury Treatment | ECOR Stock News - GuruFocus
electroCore announces new data presented on nVNS - TipRanks
electroCore, Inc. Reports Positive Data on gammaCore® for Treating Concussive Symptoms in Mild Traumatic Brain Injury at 2025 IBIA World Congress - Nasdaq
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown - GlobeNewswire
Breakthrough Study: Non-Invasive Brain Treatment Relieves 22 Concussion Symptoms in Major Clinical Trial - Stock Titan
electroCore to Participate at the Planet MicroCap Showcase - GlobeNewswire
Vagus Nerve Stimulators Market Deep Research Report with - openPR.com
Electrocore at 24th Annual Needham Virtual Healthcare Conference: Strategic Expansion Plans - Investing.com Australia
ElectroCore stock hits 52-week low at $5.3 amid challenges - Investing.com
ElectroCore stock hits 52-week low at $5.3 amid challenges By Investing.com - Investing.com South Africa
electroCore appoints new independent accounting firm By Investing.com - Investing.com Australia
electroCore appoints new independent accounting firm - Investing.com
electroCore Named One of The Americas’ Fastest Growing Companies by the Financial Times - GlobeNewswire
Financial Times Names electroCore #16 Fastest-Growing Healthcare Company in Americas - Stock Titan
Vagus Nerve Stimulators Market Size, Growth Trends and Report - openPR.com
electroCore to Participate at the Needham Virtual Healthcare Conference - The Manila Times
electroCore Showcases Breakthrough Bioelectronic Medicine Platform: CEO Headlines Needham Conference - Stock Titan
NeuroMetrix, Inc. SEC 10-K Report - TradingView
electroCore secures new VA contract through 2030 - Investing.com India
electroCore secures new VA contract through 2030 By Investing.com - Investing.com UK
electroCore Extends VA Contract for Five Years - GlobeNewswire
electroCore Wins Massive VA Deal While 585 Others Get Cut - Stock Titan
(ECOR) Technical Data - news.stocktradersdaily.com
NeuroMetrix shareholders approve merger with electroCore By Investing.com - Investing.com Australia
Market Cool On electroCore, Inc.'s (NASDAQ:ECOR) Revenues Pushing Shares 59% Lower - simplywall.st
NeuroMetrix shareholders approve merger with electroCore - Investing.com
Insider Buying: Thomas Errico Acquires 6,000 Shares of electroCo - GuruFocus.com
Trend Tracker for (ECOR) - news.stocktradersdaily.com
Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% by 2030, estimates DelveInsight - The Globe and Mail
Vagus Nerve Stimulators Market is Expected to Witness Positive - openPR.com
electroCore CEO Daniel Goldberger acquires $8,590 in stock By Investing.com - Investing.com Australia
electroCore CEO Daniel Goldberger acquires $8,590 in stock - Investing.com India
While shareholders of electroCore (NASDAQ:ECOR) are in the black over 1 year, those who bought a week ago aren't so fortunate - Simply Wall St
Q1 Earnings Estimate for electroCore Issued By HC Wainwright - Defense World
electroCore (NASDAQ:ECOR) Earns “Buy” Rating from HC Wainwright - Defense World
electroCore FY2028 EPS Forecast Increased by HC Wainwright - Defense World
LADENBURG THALM/SH SH Has Lowered Expectations for electroCore (NASDAQ:ECOR) Stock Price - Defense World
Earnings call transcript: ElectroCore Q4 2024 sees revenue rise, stock dips By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on electroCore stock, $25 target By Investing.com - Investing.com India
electroCore, Inc. (NASDAQ:ECOR) Q4 2024 Earnings Call Transcript - Insider Monkey
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
H.C. Wainwright maintains Buy on electroCore stock, $25 target - Investing.com
electroCore Inc (ECOR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
ElectroCore Reports Strong 2024 Financial Growth - TipRanks
ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Electrocore Inc Stock (ECOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):